Malaria vaccines: the stage we are at

This publication has 19 references indexed in Scilit:

• Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity toPlasmodium falciparumCS Compared to That with Either Malaria Vaccine Alone
  Infection and Immunity, 2007
• The Malaria Atlas Project: Developing Global Maps of Malaria Risk
  PLoS Medicine, 2006
• A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
  PLoS Clinical Trials, 2006
• Preclinical Evaluation of a Chimeric Malaria Vaccine Candidate in Montanide ISA 720®: Immunogenecity and Safety in Rhesus Macaques
  Human Vaccines, 2006
• Viral vectors for malaria vaccine development
  Vaccine, 2006
• Pre-erythrocytic malaria vaccines: towards greater efficacy
  Nature Reviews Immunology, 2005
• Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial
  The Lancet, 2005
• Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
  Proceedings of the National Academy of Sciences, 2005
• Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
  The Lancet, 2004
• APlasmodium falciparumcandidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses
  Proceedings of the National Academy of Sciences, 2003